Dec 18 (Reuters) - Checkpoint Therapeutics said on Monday the U.S. Food and Drug Administration declined to approve its experimental therapy to treat a type of advanced skin cancer, citing issues related to a third-party contract manufacturer. (Reporting by Mariam Sunny in Bengaluru)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.56 USD | +1.30% | -7.69% | -31.88% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.88% | 55.67M | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+46.85% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- CKPT Stock
- News Checkpoint Therapeutics, Inc.
- US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy